Searchable abstracts of presentations at key conferences in endocrinology

ea0051oc5.6 | Oral Communications 5 | BSPED2017

Phenotypic spectrum and response to recombinant human IGF1(rhIGF1) therapy in patients with homozygous intronic pseudoexon ()GH receptor mutations

Chatterjee Sumana , Rose Stephen , Mushtaq Talat , Clayton Peter , Ten Svetlana , Bhangoo Amrit , Kumbattae Uma , Dias Renuka , Shapiro Lucy , Metherell Louise , Savage Martin , Storr Helen

Objectives: Patients with homozygous 6Ψ mutations have GH insensitivity (GHI). We previously described spectrum of clinical and biochemical phenotypes of 11 6Ψ patients (David et al. JCEM 2007;92:655) and now report 9 additional patients. Response to rhIGF-I therapy has not previously been assessed.Methods: 20 6Ψ patients (12 M, 11 families, mean age 4.0±2.2 year) were diagnosed genetically in our centre. Continuous ...

ea0013p132 | Growth and development | SFEBES2007

An intronic growth hormone receptor mutation causing activation of a pseudoexon is associated with a broad spectrum of growth hormone insensitivity phenotypes

David Alessia , Camacho-Hubner Cecilia , Bhangoo Amrit , Rose Stephen , Miraki-Moud Farideh , Akker Scott , Butler Gary , Ten Svetlana , Clayton Peter , Clark Adrian , Savage Martin , Metherell Lou

Inherited growth hormone insensitivity (GHI) is usually caused by mutations in the GH receptor (GHR). Patients present with short stature associated with a mid-facial hypoplasia (Laron facial features) or with normal facial appearance. We previously described an intronic mutation in the GHR gene (A−1 to G−1 substitution in intron 6) resulting in the activation of a pseudoexon (6Ψ) in four related GHI patients with normal facial fea...